NO329439B1 - Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin - Google Patents
Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin Download PDFInfo
- Publication number
- NO329439B1 NO329439B1 NO20050542A NO20050542A NO329439B1 NO 329439 B1 NO329439 B1 NO 329439B1 NO 20050542 A NO20050542 A NO 20050542A NO 20050542 A NO20050542 A NO 20050542A NO 329439 B1 NO329439 B1 NO 329439B1
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- isopropyl
- fluorophenyl
- solution
- dihydroxyhept
- Prior art date
Links
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title claims description 21
- 159000000007 calcium salts Chemical class 0.000 title description 15
- 238000004519 manufacturing process Methods 0.000 title description 10
- 229960000672 rosuvastatin Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 133
- 238000002360 preparation method Methods 0.000 claims abstract description 58
- 239000000243 solution Substances 0.000 claims description 132
- 150000003839 salts Chemical class 0.000 claims description 82
- 238000001914 filtration Methods 0.000 claims description 66
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 63
- 239000001110 calcium chloride Substances 0.000 claims description 58
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 58
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 55
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 52
- 238000001035 drying Methods 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 37
- 238000005406 washing Methods 0.000 claims description 34
- MMTXSCWTVRMIIY-PHDIDXHHSA-N (3r,5s)-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)C=C MMTXSCWTVRMIIY-PHDIDXHHSA-N 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 239000007983 Tris buffer Chemical class 0.000 claims description 12
- 159000000000 sodium salts Chemical class 0.000 claims description 11
- 150000003863 ammonium salts Chemical class 0.000 claims description 8
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- -1 alkali metal salt Chemical class 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 150000003956 methylamines Chemical class 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 abstract description 46
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 117
- 229960002713 calcium chloride Drugs 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000002955 isolation Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 6
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 6
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 238000005292 vacuum distillation Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VHOQHIIPURUXMN-DHMAKVBVSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid;methanamine Chemical compound NC.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O VHOQHIIPURUXMN-DHMAKVBVSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- YYEWYYSTAYWBES-DHMAKVBVSA-M OC[N+](C)(CO)CO.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O Chemical compound OC[N+](C)(CO)CO.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O YYEWYYSTAYWBES-DHMAKVBVSA-M 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0218781.3A GB0218781D0 (en) | 2002-08-13 | 2002-08-13 | Chemical process |
| PCT/GB2003/003463 WO2004014872A1 (en) | 2002-08-13 | 2003-08-07 | Process for preparing the calcium salt of rosuvastatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20050542L NO20050542L (no) | 2005-02-28 |
| NO329439B1 true NO329439B1 (no) | 2010-10-18 |
Family
ID=9942204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050542A NO329439B1 (no) | 2002-08-13 | 2005-01-31 | Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7511140B2 (de) |
| EP (1) | EP1539711B1 (de) |
| JP (1) | JP4588446B2 (de) |
| KR (1) | KR101325827B1 (de) |
| CN (1) | CN100361979C (de) |
| AR (1) | AR040868A1 (de) |
| AT (1) | ATE501125T1 (de) |
| AU (1) | AU2003251369B2 (de) |
| BR (1) | BR0313394A (de) |
| CA (1) | CA2495296C (de) |
| CY (1) | CY1112412T1 (de) |
| DE (1) | DE60336326D1 (de) |
| DK (1) | DK1539711T3 (de) |
| ES (1) | ES2361009T3 (de) |
| GB (1) | GB0218781D0 (de) |
| HK (1) | HK1082735A1 (de) |
| IL (1) | IL166626A (de) |
| IS (1) | IS7728A (de) |
| MX (1) | MXPA05001582A (de) |
| MY (1) | MY135301A (de) |
| NO (1) | NO329439B1 (de) |
| NZ (1) | NZ538070A (de) |
| PL (1) | PL375296A1 (de) |
| PT (1) | PT1539711E (de) |
| RU (1) | RU2326871C2 (de) |
| SI (1) | SI1539711T1 (de) |
| TW (1) | TWI316058B (de) |
| UA (1) | UA83805C2 (de) |
| WO (1) | WO2004014872A1 (de) |
| ZA (1) | ZA200500745B (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| GB0011120D0 (en) | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
| NL1015744C2 (nl) | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
| HUP0401248A3 (en) | 2001-07-13 | 2004-11-29 | Astrazeneca Uk Ltd | Preparation of aminopyrimidine compounds and new intermediates |
| EP1323717A1 (de) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten |
| EP1375493A1 (de) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Verfahren zur Herstellung von Dioxanessigsäureester |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| KR101060215B1 (ko) | 2002-12-16 | 2011-08-29 | 아스트라제네카 유케이 리미티드 | 피리미딘 화합물의 제조 방법 |
| GB0312896D0 (en) * | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| CA2537271A1 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of rosuvastatin calcium |
| UY28501A1 (es) * | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| TW200526596A (en) | 2003-11-24 | 2005-08-16 | Teva Pharma | Crystalline ammonium salts of rosuvastatin |
| CA2546894C (en) * | 2003-12-02 | 2009-09-08 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| EP1737828A1 (de) * | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphe magnesiumsalze von rosuvastatin |
| US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
| US7179916B2 (en) | 2004-07-13 | 2007-02-20 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin |
| EP1797046A2 (de) * | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Neue verfahren zur herstellung von amorphem rosuvastatincalcium und neue polymorphe form von rosuvastatinnatrium |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| EP1845092B1 (de) * | 2004-12-23 | 2010-09-01 | Hui Yao | Pyrimidinonverbindungen, ihre herstellung und ihre verwendung |
| GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| EP1844021A1 (de) * | 2005-01-31 | 2007-10-17 | Ciba Specialty Chemicals Holding Inc. | Kristalline formen eines rosuvastatin-calciumsalzes |
| KR100945763B1 (ko) | 2005-02-22 | 2010-03-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴의 제조 방법 |
| CA2612587C (en) * | 2005-06-24 | 2013-02-19 | Lek Pharmaceuticals D.D. | Process for preparing amorphous rosuvastatin calcium free of impurities |
| ES2564807T5 (es) | 2005-06-24 | 2019-02-26 | Lek Pharmaceuticals | Proceso para preparación de rosuvastatina de calcio amorfa pura |
| GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
| EP1922065A4 (de) * | 2005-08-04 | 2009-11-11 | Transform Pharmaceuticals Inc | Neue formulierungen mit fenofibrat und einem statin und relevante behandlungsverfahren |
| EP1919880A2 (de) | 2005-08-16 | 2008-05-14 | Teva Pharmaceutical Industries Ltd. | Rosuvastatincalcium mit geringem gehalt an salzhaltigen nebenprodukten |
| KR20070062996A (ko) | 2005-08-16 | 2007-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 로수바스타틴 중간체 |
| PL1924246T3 (pl) | 2005-09-15 | 2016-04-29 | Genzyme Corp | Preparat polimerów amin w saszetkach |
| ES2564250T3 (es) | 2006-05-03 | 2016-03-21 | Msn Laboratories Private Limited | Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas |
| SI2086945T1 (sl) | 2006-10-09 | 2016-05-31 | Msn Laboratories Private Limited | Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli |
| US8318933B2 (en) * | 2006-10-31 | 2012-11-27 | Aurobindo Pharma Ltd | Process for preparing rosuvastatin calcium |
| TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
| WO2008072078A1 (en) | 2006-12-13 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin caclium |
| EP2125754B1 (de) * | 2007-02-08 | 2012-04-11 | Aurobindo Pharma Limited | Verfahren zur herstellung von rosuvastatin-calcium |
| JP2010501643A (ja) * | 2007-07-12 | 2010-01-21 | テバ ファーマシューティカル インダストリーズ リミティド | 薄膜蒸発及び化学的手法によるロスバスタチン中間体の精製 |
| HU230637B1 (hu) * | 2007-10-12 | 2017-05-29 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin intermedierek előállítására |
| HU230981B1 (hu) * | 2007-10-12 | 2019-08-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin só előállítására |
| WO2009143776A1 (zh) | 2008-05-27 | 2009-12-03 | 常州制药厂有限公司 | 瑞舒伐他汀钙盐的制备方法及其中间体 |
| WO2010035284A2 (en) * | 2008-09-26 | 2010-04-01 | Matrix Laboratories Ltd | An improved process for the preparation of rosuvastatin calcium |
| WO2010038124A1 (en) * | 2008-09-30 | 2010-04-08 | Aurobindo Pharma Limited | An improved process for preparing pyrimidine propenaldehyde |
| US8507513B2 (en) * | 2009-01-15 | 2013-08-13 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Process for the preparation of rosuvastatin salts |
| EP2387561A4 (de) | 2009-01-19 | 2012-07-25 | Msn Lab Ltd | Verbessertes verfahren zur herstellung von hochreiner (3r,5s)-7-[2-cyclopropyl-4-(4-fluorphenyl) chinolin-3-yl]-3,5-dihydroxy-6(e)-heptensäure und pharmazeutisch akzeptable salze daraus |
| WO2011086584A2 (en) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| WO2011132172A1 (en) | 2010-04-23 | 2011-10-27 | Ranbaxy Laboratories Limited | NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS |
| HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
| US9676729B2 (en) * | 2013-03-29 | 2017-06-13 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Amine salts of pitavastatin and rosuvastatin |
| TWM477638U (zh) * | 2013-12-12 | 2014-05-01 | 三緯國際立體列印科技股份有限公司 | 加熱平台與立體列印裝置 |
| EP3572075A2 (de) | 2017-01-23 | 2019-11-27 | Dong Wha Pharm. Co., Ltd. | Komplexe formulierung mit hmg-coa-reduktase-hemmer und clopidogrel |
| EP3976805A1 (de) | 2019-05-27 | 2022-04-06 | Immatics US, Inc. | Virale vektoren und ihre verwendung in der adoptiven zelltherapie |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| SI26268A (sl) | 2021-11-18 | 2023-05-31 | Zupet Rok | Postopek za pripravo hidratirane oblike perindopril l-arginina |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US663641A (en) * | 1900-10-11 | 1900-12-11 | Charles A Ruebekam | Burial-casket. |
| US4645858A (en) | 1982-03-22 | 1987-02-24 | G. D. Searle & Co. | Pentanedioic acid derivatives |
| DE3741509A1 (de) | 1987-12-08 | 1989-06-22 | Hoechst Ag | Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte |
| WO1990003973A1 (en) | 1988-10-06 | 1990-04-19 | Sandoz Ag | Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them |
| US5026698A (en) | 1988-11-02 | 1991-06-25 | Nissan Chemical Industries, Ltd. | Thienopyridine type mevalonolactones |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
| US5278313A (en) | 1992-03-27 | 1994-01-11 | E. R. Squibb & Sons, Inc. | Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors |
| SG44830A1 (en) | 1992-07-02 | 1997-12-19 | Hoechst Ag | Process for preparing tert-butyl 93R,5S) -6 Hydroxy-3,5-O-Isopropylidene-3, 5-Dihydroxyhexanoate |
| SK284202B6 (sk) | 1995-07-17 | 2004-10-05 | Warner-Lambert Company | Kryštalické formy I, II a IV atorvastatínu, to je semivápenatej soli kyseliny [R-(R*,R*)]-2-(4-fluórfenyl)-beta,delta-dihydroxy- 5-(1-metyletyl)-3-fenyl-4-(fenylamino)karbonyl]-1H-pyrol-1- heptánovej, alebo jeho hydrátu, farmaceutické kompozície obsahujúce uvedené kryštalické formy a kryštalické formy na použitie ako liečivo |
| FR2741620B1 (fr) | 1995-11-28 | 1997-12-26 | Oreal | Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline |
| US6278001B1 (en) | 1995-11-28 | 2001-08-21 | L'oréal | Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping |
| ES2194202T3 (es) | 1996-06-24 | 2003-11-16 | Novartis Ag | Compuestos polimorfos. |
| CZ299566B6 (cs) | 1998-12-10 | 2008-09-03 | Kaneka Corporation | Zpusob výroby simvastatinu |
| GB9900339D0 (en) * | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
| GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| HU228303B1 (hu) * | 1999-07-13 | 2013-03-28 | Lonza Ag | Eljárás 2-amino-4-(4-fluorfenil)-6-alkil-pirimidin-5-karboxilát-származékok elõállítására |
| AU7717500A (en) | 1999-09-30 | 2001-04-30 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
| PL355805A1 (en) | 1999-11-17 | 2004-05-17 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| AU2000254249A1 (en) | 2000-03-28 | 2001-10-08 | Biocon India Limited | Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1- |
| GB0011120D0 (en) * | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
| GB0011163D0 (en) | 2000-05-10 | 2000-06-28 | Astrazeneca Ab | Chemical compound |
| NL1015744C2 (nl) | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
| AU2002211462A1 (en) | 2000-10-05 | 2002-04-22 | Teva Gyogyszergyar Reszvenytarsasag | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
| SK7212003A3 (en) | 2000-11-16 | 2004-03-02 | Teva Pharma | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| NL1017548C2 (nl) | 2001-03-09 | 2002-09-10 | Synthon Bv | Een lactonisatie proces. |
| IN190564B (de) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| ES2214169T1 (es) | 2001-06-06 | 2004-09-16 | Bristol-Myers Squibb Company | Procedimiento de preparacion de sulfonas quirales dioles e inhibidores del dihidroxiacido hmg coa reductasa. |
| HUP0401248A3 (en) * | 2001-07-13 | 2004-11-29 | Astrazeneca Uk Ltd | Preparation of aminopyrimidine compounds and new intermediates |
| IL160077A0 (en) * | 2001-08-16 | 2004-06-20 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| IL160043A0 (en) | 2001-08-22 | 2004-06-20 | Ciba Sc Holding Ag | Process for the preparation of indole derivatives |
| JP2005512516A (ja) | 2001-09-24 | 2005-05-12 | メルク エンド カムパニー インコーポレーテッド | スタチン薬物の組合せのスクリーニング方法および選択方法 |
| EP1323717A1 (de) * | 2001-12-27 | 2003-07-02 | Dsm N.V. | Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten |
| KR100511533B1 (ko) | 2002-04-09 | 2005-08-31 | 임광민 | 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법 |
| EP1585736A2 (de) | 2002-05-21 | 2005-10-19 | Ranbaxy Laboratories, Ltd. | Verfahren zur herstellung von rosuvastatin |
| EP1375493A1 (de) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Verfahren zur Herstellung von Dioxanessigsäureester |
| GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| EP1578733B1 (de) | 2002-12-10 | 2011-03-09 | Ranbaxy Laboratories Limited | Verfahren zur herstellung von rosuvastatin |
| KR101060215B1 (ko) * | 2002-12-16 | 2011-08-29 | 아스트라제네카 유케이 리미티드 | 피리미딘 화합물의 제조 방법 |
| US8367848B2 (en) | 2003-04-11 | 2013-02-05 | Lek Pharmaceuticals D.D. | Process for the preparation of amorphous calcium salt of atorvastatin |
| WO2004103977A2 (en) | 2003-05-21 | 2004-12-02 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of pyrimidine derivatives |
| GB0312896D0 (en) * | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| WO2005005384A1 (en) | 2003-07-15 | 2005-01-20 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
| CA2537271A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of rosuvastatin calcium |
| UY28501A1 (es) * | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| CN1886383A (zh) | 2003-10-22 | 2006-12-27 | 兰贝克赛实验室有限公司 | 无定形罗苏伐他汀钙的制备方法 |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| DE10352659B4 (de) | 2003-11-11 | 2007-09-13 | Ratiopharm Gmbh | Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren |
| TW200526596A (en) | 2003-11-24 | 2005-08-16 | Teva Pharma | Crystalline ammonium salts of rosuvastatin |
| US7028631B2 (en) * | 2003-11-24 | 2006-04-18 | The Boeing Company | Gliding submersible transport system |
| CA2546894C (en) | 2003-12-02 | 2009-09-08 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| WO2005054207A1 (en) | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
| CA2645396A1 (en) | 2003-12-24 | 2005-07-14 | Teva Pharmaceutical Industries, Ltd | Process for preparation of statins with high syn to anti ratio |
| CZ200486A3 (cs) | 2004-01-16 | 2005-08-17 | Zentiva, A.S. | Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny |
| EP1709008A1 (de) | 2004-01-19 | 2006-10-11 | Ranbaxy Laboratories Limited | Salze von hmg-coa-reduktase-inhibitoren und deren verwendung |
| EP1737828A1 (de) | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphe magnesiumsalze von rosuvastatin |
| US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
| GB0406757D0 (en) | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
| US7161004B2 (en) | 2004-06-21 | 2007-01-09 | Dr. Reddy's Laboratories Limited | Processes to produce intermediates for rosuvastatin |
| US7179916B2 (en) | 2004-07-13 | 2007-02-20 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin |
| EP1797046A2 (de) | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Neue verfahren zur herstellung von amorphem rosuvastatincalcium und neue polymorphe form von rosuvastatinnatrium |
| GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| EP1844021A1 (de) | 2005-01-31 | 2007-10-17 | Ciba Specialty Chemicals Holding Inc. | Kristalline formen eines rosuvastatin-calciumsalzes |
| CA2498978A1 (en) | 2005-02-28 | 2006-08-28 | Apotex Pharmachem Inc. | An improved process for the preparation of atorvastatin and intermediates |
| GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
| TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
-
2002
- 2002-08-13 GB GBGB0218781.3A patent/GB0218781D0/en not_active Ceased
-
2003
- 2003-07-08 UA UAA200500711A patent/UA83805C2/uk unknown
- 2003-08-07 DE DE60336326T patent/DE60336326D1/de not_active Expired - Lifetime
- 2003-08-07 AU AU2003251369A patent/AU2003251369B2/en not_active Expired
- 2003-08-07 NZ NZ538070A patent/NZ538070A/en not_active IP Right Cessation
- 2003-08-07 KR KR1020057002408A patent/KR101325827B1/ko active IP Right Grant
- 2003-08-07 TW TW092121663A patent/TWI316058B/zh not_active IP Right Cessation
- 2003-08-07 BR BR0313394-0A patent/BR0313394A/pt not_active IP Right Cessation
- 2003-08-07 CN CNB038239949A patent/CN100361979C/zh not_active Expired - Lifetime
- 2003-08-07 AT AT03784274T patent/ATE501125T1/de active
- 2003-08-07 PL PL03375296A patent/PL375296A1/xx unknown
- 2003-08-07 SI SI200331993T patent/SI1539711T1/sl unknown
- 2003-08-07 JP JP2004527041A patent/JP4588446B2/ja not_active Expired - Lifetime
- 2003-08-07 US US10/524,235 patent/US7511140B2/en not_active Expired - Lifetime
- 2003-08-07 MX MXPA05001582A patent/MXPA05001582A/es active IP Right Grant
- 2003-08-07 DK DK03784274.7T patent/DK1539711T3/da active
- 2003-08-07 ES ES03784274T patent/ES2361009T3/es not_active Expired - Lifetime
- 2003-08-07 RU RU2005102391/04A patent/RU2326871C2/ru active
- 2003-08-07 WO PCT/GB2003/003463 patent/WO2004014872A1/en active Application Filing
- 2003-08-07 PT PT03784274T patent/PT1539711E/pt unknown
- 2003-08-07 CA CA2495296A patent/CA2495296C/en not_active Expired - Fee Related
- 2003-08-07 EP EP03784274A patent/EP1539711B1/de not_active Revoked
- 2003-08-11 MY MYPI20033048A patent/MY135301A/en unknown
- 2003-08-13 AR AR20030102929A patent/AR040868A1/es unknown
-
2005
- 2005-01-31 NO NO20050542A patent/NO329439B1/no not_active IP Right Cessation
- 2005-02-01 IL IL166626A patent/IL166626A/en unknown
- 2005-03-08 IS IS7728A patent/IS7728A/is unknown
-
2006
- 2006-01-10 ZA ZA200500745A patent/ZA200500745B/en unknown
- 2006-02-27 HK HK06102591A patent/HK1082735A1/xx not_active IP Right Cessation
-
2009
- 2009-02-13 US US12/371,359 patent/US7842807B2/en not_active Expired - Lifetime
-
2011
- 2011-05-09 CY CY20111100442T patent/CY1112412T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329439B1 (no) | Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin | |
| US8063213B2 (en) | Production of rosuvastatin calcium salt | |
| CN1161343C (zh) | 氯代嘧啶中间体 | |
| US8394961B2 (en) | Method for the preparation of dabigatran | |
| US20180297945A1 (en) | Polymorphic form of pyrrole derivative and intermediate thereof | |
| NO313878B1 (no) | FremgangsmÕte ved fremstilling av N-(amino-4,6- dihalogenpyrimidin)formamider | |
| EP2755959A1 (de) | Rilpivirin-hydrochlorid | |
| EP2702044A2 (de) | Verfahren für rilpivirin | |
| RU2228929C2 (ru) | Способ получения 3s-3-амино-3-пиридилпропионовой кислоты и ее производных и промежуточное вещество | |
| WO2008093205A2 (en) | A method for the purification of rosuvastatin intermediate | |
| JP4209022B2 (ja) | イソシアノ酢酸アルキルエステル類の製造法 | |
| WO2011121598A1 (en) | Crystalline 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3(r)-hydroxy-5-oxo-hept-6-enoic acid methyl ester and process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |